| | Publications:
Books:
Hall DP. Breaking Through Depression: Biblical
and Medical Approaches to Wholeness. Harvest House Publishers. Eugene, Oregon. 2009.
Hall
DP. Handbook of Psychiatric Drugs. Current Clinical Strategies Publishing. Laguna Hills, CA. 1997.
Hall
DP. 200 Tips for Passing the Oral Psychiatry Boards.Hanley and Belphus, Inc. Philadelphia, PA. 1997.
Selected
Journal Articles:
Waits W, Hall DP. Gabapentin in the treatment of bipolar disorder. Jefferson
Journal of Psychiatry. 1998; 14:24-29.
Hall DP. Peacekeeping duty and PTSD (letter). American Journal
of Psychiatry. 1997; 154:1482-1483.
Hall DP, Cipriano ED. Frustrated aggression and psychiatric casualties
of Operation Uphold Democracy.Journal of Nervous and Mental Disease. 1996; 184:377-378.
Hall DP. Stress,
suicide, and military service during Operation Uphold Democracy.Military Medicine. 1996; 161:159-162.
Hall
DP, Benedek DM. Ultradian cycles of mood in normal and depressed subjects.Jefferson Journal of Psychiatry. 1996;
13:9-17.
Hall DP, Benedek DM. Adjustment disorder criteria (letter). Hospital and Community Psychiatry.
1993; 44:592.
Hall DP. A widow's grief: the language of the heart. Journal of the American Medical Association.
1992; 268: 871-872.
Hall DP, Young SA. Frontal lobe cerebral aneurysm rupture presenting as psychosis.Journal
of Neurology, Neurosurgery, and Psychiatry. 1992; 55:1207-1208.
Hall DP, Sing HC, Romanoski, AJ. The identification
and characterization of greater mood variance in depression.American Journal of Psychiatry. 1991; 148:1341-1345.
Hall DP. Exploring frontal lobe dysfunction in schizophrenia with positron emission tomography.Jefferson Journal
of Psychiatry. 1990; 8:50-58.
Ksir C, Hakan R, Hall DP, Kellar KJ. Exposure to nicotine enhances the behavioral
stimulant effect of nicotine and increases binding of 3H-acetylcholine to nicotinic receptors.Neuropharmacology.
1985; 24:527-531.
Kellar KJ, Schwartz RD, Martino AM, Hall DP. 3H- acetylcholine binding to muscarinic an nicotinic
cholinergic receptors in brain: utility for study of neuropsychiatric disease. Neuropharmacology. 1984; 7 (suppl.1):954-955.
|